Ecomectin 5 mg/ml Pour-on Solution for Cattle

Main information

  • Trade name:
  • Ecomectin 5 mg/ml Pour-on Solution for Cattle
  • Available from:
  • Eco Animal Health Ltd
  • Prescription type:
  • POM-VPS
  • Medicine type:
  • Veterinary

Documents

Localization

  • Available in:
  • Ecomectin 5 mg/ml Pour-on Solution for Cattle
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • VMD
  • Authorization date:
  • 06-08-2007
  • Last update:
  • 23-04-2015

Patient Information leaflet


Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 1 of 7

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ecomectin 5 mg/ml Pour-on Solution for Cattle

Coopermec Vet – 5 mg/ml Pour-on Solution (Sweden)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml contains:

Active substance(s):

Ivermectin…………………5 mg

Excipient(s):

Benzyl alcohol…………….10 mg

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Pour-on solution.

A clear, colourless solution

4. CLINICAL PARTICULARS

4.1 Target species

Cattle

4.2 Indications for use, specifying the target species

In cattle: For the treatment of infections with the following parasites

Gastro-intestinal worms -

Haemonchus placei (adult andL4)

Ostertagia ostertagi (adult and L4, including inhibited larvae)

Trichostrongylus axei (adult and L4)

Trichostrongylus colubriformis (adult and L4)

Cooperia punctata (adult only)

Cooperia oncophora (adult only)

Strongyloides papillosus (adult only)

Oesophagostomum radiatum, (adult and L4)

Lungworm (adult and L4) – Dictyocaulus viviparus.

Warbles (parasitic stages) – Hypoderma bovis, Hypoderma lineatum.

Mange mites – Sarcoptes scabiei var. bovis. The product may also be used to

reduce infection of the mange mite Chorioptes bovis, but complete elimination

may not occur.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 2 of 7

Sucking and biting lice – Linognathus vituli, Haematopinus eurysternus, Bovicola

(Damalinia) bovis.

The product has persistent activity against infections acquired with

Trichostrongylus axei and Cooperia spp. up to 14 days after treatment, but only in

the case of group treatment; Ostertagia ostertagi and Oesophagostomum

radiatum up to 21 days after treatment; Dictyocaulus viviparus up to 28 days after

treatment. It also has persistent activity against horn flies (Haematobia irritans) for

up to 28 days after treatment; partial efficacy against Haematobia irritans may last

for up to 35 days post application.

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active ingredient.

The product has been formulated for topical application specifically for cattle. It

should not be administered to other species as severe adverse reactions including

fatalities in dogs, may occur

4.4 Special warnings for each target species

Do not treat cattle when their hide is wet.

Do not treat cattle if rain is expected, as rain within 2 hours of treatment may

reduce efficacy.

Do not apply to areas of skin which have mange scabs or other lesions, or to

areas contaminated with mud or manure.

.

Care should be taken to avoid the following practices because they increase the

risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an

extended period of time.

- Underdosing, which may be due to underestimation of body weight,

misadministration of the product, or lack of calibration of the dosing device.

Suspected clinical cases of resistance to anthelmintics should be further

investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test).

Where the results of the test(s) strongly suggest resistance to a particular

anthelmintic, an anthelmintic belonging to another pharmacological class and

having a different mode of action should be used.

Resistance to ivermectin has been reported in Ostertagia ostertagi in cattle.

Therefore, the use of this product should be based on local (regional, farm)

epidemiological information about susceptibility of this helminth species and

recommendations on how to limit further selection for resistance to anthelmintics

4.5 Special precautions for use

Special precautions for use in animals

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 3 of 7

To avoid secondary reactions due to the death of Hypoderma larvae in the

oesophagus or in the spine, it is recommended to administer the product at the

end of warble fly activity and before the larvae reach their resting sites.

Cases of intolerance with fatal outcome are reported in dogs, especially Collies,

old English Sheepdogs and related breeds or crosses, and also in

turtles/tortoises.” Do not allow these species to come in contact with this product.

It is recommended to treat all animals within a herd or group.

The shedding of nematode eggs can continue for some time after treatment.

Close container after use.

Special precautions to be taken by the person administering the veterinary

medicinal product to animals

May be irritating to human skin and eyes and the user should be careful not to

apply it to himself or other persons.

Operators should wear rubber gloves, boots, goggles and a waterproof coat when

applying the product. Protective clothing should be washed after use.

As absorption through skin can occur, in the event of accidental skin contact, wash

the affected area immediately with soap and water.

If accidental eye exposure occurs, flush the eyes immediately with water and get

medical attention.

Do not smoke, eat or drink while handling the product.

Wash hands after use.

Use only in well ventilated areas or outdoors.

HIGHLY INFLAMMABLE, keep away from heat, sparks, open flame or other

sources of ignition.

4.6 Adverse reactions (frequency and seriousness)

None known

4.7 Use during pregnancy, lactation or lay

Studies in laboratory animals have shown neither embryotoxic nor

teratogenic effects with ivermectin.

Can be used during pregnancy and lactation provided that the milk is not intended

for human consumption.

Please also see section 4.11

4.8 Interaction with other medicinal products and other forms of interaction

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 4 of 7

Do not combine ivermectin treatment with vaccination against lungworms. If

vaccinated animals are to be treated, treatment should not be carried out within a

period of 28 days before or after vaccination.

4.9 Amounts to be administered and administration route

To ensure administration of a correct dose, body weight should be determined as

accurately as possible.

If animals are to be treated collectively rather than individually they should be

grouped according to their bodyweight and dosed accordingly, in order to avoid

under- or over- dosing.

Dosage

1ml per 10kg body weight (based on a recommended dosage level of 500

micrograms per kg body weight).

Administration

For topical application.

The formulation should be applied along the mid-line of the back in a narrow strip

between the withers and tailhead.

The 250 ml and 1.0 litre packs must be used with appropriate dosing equipment.

Instructions for using the dispensing chamber:

a) Take dip tube and insert end into base of measuring cap with slotted end

going to the bottom of the container.

b) Remove shipping cap from container.

c) Screw measuring cap onto container.

d) Select the correct dose rate by rotating the adjuster cap in either direction to

position the dose indicator to the appropriate dose.

e) Gently squeeze the bottle to fill to level (any excess will return to the bottle) and

then tip and apply to animal along backline.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No signs of toxicity appeared in trials up to 3 times the recommended dose rate.

Clinical symptoms of ivermectin toxicity include ataxia and depression.

No antidote has been identified. In case of overdose, symptomatic treatment

should be given.

4.11 Withdrawal period(s)

Meat and offal: 31 days.

Milk: Not permitted for use in lactating cattle producing milk for human

consumption. Do not use in non-lactating dairy cows, including pregnant dairy

heifers, within 60 days of calving.

5. PHARMACOLOGICAL PROPERTIES

ATC vet code: QP54AA01.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 5 of 7

Pharmacotherapeutic group: endectocides, avermectins

5.1 Pharmacodynamic properties

Ivermectin is a mixture of two compounds belonging to the avermectin family,

which are a macrocyclic lactone group of endectocides. Avermectin is a microbial

metabolite of the soil organism Streptomyces avermilitis.

It is generally accepted that ivermectin exerts its action in two main ways,

interference with neurotransmission and opening chloride ion channels. The effect

of ivermectin on the parasitic CNS is considered to operate through glutamate-

mediated chloride channels. Compounds of this class may also interact with other

ligand-gated chloride channels, such as those gated by the neurotransmitter

gamma-aminobutyric acid (GABA).

The opening of pre-synaptic chloride ion channels results in an efflux of chloride

ions and depolarisation of the nerve terminal. These effects interfere with normal

neurotransmission between nerves and muscles, resulting in parasite paralysis

and eventual death.

5.2 Pharmacokinetic particulars

After administration of the product, the ivermectin is absorbed through the skin into

the circulation of the treated animal. The maximum concentration in plasma occurs

around 70 hours after application. Peak concentrations of about 7 ng/ml are

obtained.

The residual antiparasitic effect of ivermectin is due to its persistence, which in

turn is due in part to its long intrinsic half-life (t

1/2ß of approximately 210 hours), in

part to its relatively high plasma protein binding (80% in cattle; binding remains

relatively constant over time) and in part to the nature and type of the ivermectin

formulation.

Elimination is in the faeces (via biliary excretion). Over 60% of the dose is

excreted after 3 days.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Isopropyl alcohol

Polypropoxylate-2-myristyl ether propionate

N-Methylpyrrolidone

Benzyl Alcohol

Water

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life after first opening the immediate packaging: 6 months

6.4. Special precautions for storage

Do not store above 25 °

C.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 6 of 7

Protect from light.

Store in the original container, tightly closed.

Keep the container in the outer carton.

If stored at temperatures below 0°C, the solution may appear cloudy. Allowing to

warm at room temperature will restore normal appearance without affecting

efficacy.

6.5 Nature and composition of immediate packaging

250 ml white fluorinated high-density polyethylene bottle with a drawing tube and

measuring device.

1.0 L white fluorinated high-density polyethylene bottle with a drawing tube and

measuring device.

2.5 L white fluorinated high-density polyethylene back-pack with polypropylene

strap and vented cap

250 ml natural fluorinated high-density polyethylene pour-on bottle with internal

graduated calibration chamber

5.0 L white fluorinated high-density polyethylene back-pack with polypropylene

strap and vented cap

Closure: White polypropylene screw-cap.

Not all pack sizes may be marketed

6.6 Special precautions for the disposal of unused veterinary medicinal

product or waste materials derived from the use of such products

THE PRODUCT IS EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do

not contaminate surface water or ditches with product or the used container. Any

unused veterinary medicinal product or waste material derived from such veterinary

medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

ECO Animal Health Ltd.

78 Coombe Road

New Malden

Surrey KT3 4QS

UNITED KINGDOM

8. MARKETING AUTHORISATION NUMBER

Vm 13277/4021

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 7 of 7

9. DATE OF FIRST AUTHORISATION

06 th

August 2007

10 DATE OF REVISION OF THE TEXT

November 2011

Summary of Product characteristics


Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 1 of 7

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ecomectin 5 mg/ml Pour-on Solution for Cattle

Coopermec Vet – 5 mg/ml Pour-on Solution (Sweden)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml contains:

Active substance(s):

Ivermectin…………………5 mg

Excipient(s):

Benzyl alcohol…………….10 mg

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Pour-on solution.

A clear, colourless solution

4. CLINICAL PARTICULARS

4.1 Target species

Cattle

4.2 Indications for use, specifying the target species

In cattle: For the treatment of infections with the following parasites

Gastro-intestinal worms -

Haemonchus placei (adult andL4)

Ostertagia ostertagi (adult and L4, including inhibited larvae)

Trichostrongylus axei (adult and L4)

Trichostrongylus colubriformis (adult and L4)

Cooperia punctata (adult only)

Cooperia oncophora (adult only)

Strongyloides papillosus (adult only)

Oesophagostomum radiatum, (adult and L4)

Lungworm (adult and L4) – Dictyocaulus viviparus.

Warbles (parasitic stages) – Hypoderma bovis, Hypoderma lineatum.

Mange mites – Sarcoptes scabiei var. bovis. The product may also be used to

reduce infection of the mange mite Chorioptes bovis, but complete elimination

may not occur.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 2 of 7

Sucking and biting lice – Linognathus vituli, Haematopinus eurysternus, Bovicola

(Damalinia) bovis.

The product has persistent activity against infections acquired with

Trichostrongylus axei and Cooperia spp. up to 14 days after treatment, but only in

the case of group treatment; Ostertagia ostertagi and Oesophagostomum

radiatum up to 21 days after treatment; Dictyocaulus viviparus up to 28 days after

treatment. It also has persistent activity against horn flies (Haematobia irritans) for

up to 28 days after treatment; partial efficacy against Haematobia irritans may last

for up to 35 days post application.

4.3 Contraindications

Do not use in cases of known hypersensitivity to the active ingredient.

The product has been formulated for topical application specifically for cattle. It

should not be administered to other species as severe adverse reactions including

fatalities in dogs, may occur

4.4 Special warnings for each target species

Do not treat cattle when their hide is wet.

Do not treat cattle if rain is expected, as rain within 2 hours of treatment may

reduce efficacy.

Do not apply to areas of skin which have mange scabs or other lesions, or to

areas contaminated with mud or manure.

.

Care should be taken to avoid the following practices because they increase the

risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an

extended period of time.

- Underdosing, which may be due to underestimation of body weight,

misadministration of the product, or lack of calibration of the dosing device.

Suspected clinical cases of resistance to anthelmintics should be further

investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test).

Where the results of the test(s) strongly suggest resistance to a particular

anthelmintic, an anthelmintic belonging to another pharmacological class and

having a different mode of action should be used.

Resistance to ivermectin has been reported in Ostertagia ostertagi in cattle.

Therefore, the use of this product should be based on local (regional, farm)

epidemiological information about susceptibility of this helminth species and

recommendations on how to limit further selection for resistance to anthelmintics

4.5 Special precautions for use

Special precautions for use in animals

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 3 of 7

To avoid secondary reactions due to the death of Hypoderma larvae in the

oesophagus or in the spine, it is recommended to administer the product at the

end of warble fly activity and before the larvae reach their resting sites.

Cases of intolerance with fatal outcome are reported in dogs, especially Collies,

old English Sheepdogs and related breeds or crosses, and also in

turtles/tortoises.” Do not allow these species to come in contact with this product.

It is recommended to treat all animals within a herd or group.

The shedding of nematode eggs can continue for some time after treatment.

Close container after use.

Special precautions to be taken by the person administering the veterinary

medicinal product to animals

May be irritating to human skin and eyes and the user should be careful not to

apply it to himself or other persons.

Operators should wear rubber gloves, boots, goggles and a waterproof coat when

applying the product. Protective clothing should be washed after use.

As absorption through skin can occur, in the event of accidental skin contact, wash

the affected area immediately with soap and water.

If accidental eye exposure occurs, flush the eyes immediately with water and get

medical attention.

Do not smoke, eat or drink while handling the product.

Wash hands after use.

Use only in well ventilated areas or outdoors.

HIGHLY INFLAMMABLE, keep away from heat, sparks, open flame or other

sources of ignition.

4.6 Adverse reactions (frequency and seriousness)

None known

4.7 Use during pregnancy, lactation or lay

Studies in laboratory animals have shown neither embryotoxic nor

teratogenic effects with ivermectin.

Can be used during pregnancy and lactation provided that the milk is not intended

for human consumption.

Please also see section 4.11

4.8 Interaction with other medicinal products and other forms of interaction

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 4 of 7

Do not combine ivermectin treatment with vaccination against lungworms. If

vaccinated animals are to be treated, treatment should not be carried out within a

period of 28 days before or after vaccination.

4.9 Amounts to be administered and administration route

To ensure administration of a correct dose, body weight should be determined as

accurately as possible.

If animals are to be treated collectively rather than individually they should be

grouped according to their bodyweight and dosed accordingly, in order to avoid

under- or over- dosing.

Dosage

1ml per 10kg body weight (based on a recommended dosage level of 500

micrograms per kg body weight).

Administration

For topical application.

The formulation should be applied along the mid-line of the back in a narrow strip

between the withers and tailhead.

The 250 ml and 1.0 litre packs must be used with appropriate dosing equipment.

Instructions for using the dispensing chamber:

a) Take dip tube and insert end into base of measuring cap with slotted end

going to the bottom of the container.

b) Remove shipping cap from container.

c) Screw measuring cap onto container.

d) Select the correct dose rate by rotating the adjuster cap in either direction to

position the dose indicator to the appropriate dose.

e) Gently squeeze the bottle to fill to level (any excess will return to the bottle) and

then tip and apply to animal along backline.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No signs of toxicity appeared in trials up to 3 times the recommended dose rate.

Clinical symptoms of ivermectin toxicity include ataxia and depression.

No antidote has been identified. In case of overdose, symptomatic treatment

should be given.

4.11 Withdrawal period(s)

Meat and offal: 31 days.

Milk: Not permitted for use in lactating cattle producing milk for human

consumption. Do not use in non-lactating dairy cows, including pregnant dairy

heifers, within 60 days of calving.

5. PHARMACOLOGICAL PROPERTIES

ATC vet code: QP54AA01.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 5 of 7

Pharmacotherapeutic group: endectocides, avermectins

5.1 Pharmacodynamic properties

Ivermectin is a mixture of two compounds belonging to the avermectin family,

which are a macrocyclic lactone group of endectocides. Avermectin is a microbial

metabolite of the soil organism Streptomyces avermilitis.

It is generally accepted that ivermectin exerts its action in two main ways,

interference with neurotransmission and opening chloride ion channels. The effect

of ivermectin on the parasitic CNS is considered to operate through glutamate-

mediated chloride channels. Compounds of this class may also interact with other

ligand-gated chloride channels, such as those gated by the neurotransmitter

gamma-aminobutyric acid (GABA).

The opening of pre-synaptic chloride ion channels results in an efflux of chloride

ions and depolarisation of the nerve terminal. These effects interfere with normal

neurotransmission between nerves and muscles, resulting in parasite paralysis

and eventual death.

5.2 Pharmacokinetic particulars

After administration of the product, the ivermectin is absorbed through the skin into

the circulation of the treated animal. The maximum concentration in plasma occurs

around 70 hours after application. Peak concentrations of about 7 ng/ml are

obtained.

The residual antiparasitic effect of ivermectin is due to its persistence, which in

turn is due in part to its long intrinsic half-life (t

1/2ß of approximately 210 hours), in

part to its relatively high plasma protein binding (80% in cattle; binding remains

relatively constant over time) and in part to the nature and type of the ivermectin

formulation.

Elimination is in the faeces (via biliary excretion). Over 60% of the dose is

excreted after 3 days.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Isopropyl alcohol

Polypropoxylate-2-myristyl ether propionate

N-Methylpyrrolidone

Benzyl Alcohol

Water

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life after first opening the immediate packaging: 6 months

6.4. Special precautions for storage

Do not store above 25 °

C.

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 6 of 7

Protect from light.

Store in the original container, tightly closed.

Keep the container in the outer carton.

If stored at temperatures below 0°C, the solution may appear cloudy. Allowing to

warm at room temperature will restore normal appearance without affecting

efficacy.

6.5 Nature and composition of immediate packaging

250 ml white fluorinated high-density polyethylene bottle with a drawing tube and

measuring device.

1.0 L white fluorinated high-density polyethylene bottle with a drawing tube and

measuring device.

2.5 L white fluorinated high-density polyethylene back-pack with polypropylene

strap and vented cap

250 ml natural fluorinated high-density polyethylene pour-on bottle with internal

graduated calibration chamber

5.0 L white fluorinated high-density polyethylene back-pack with polypropylene

strap and vented cap

Closure: White polypropylene screw-cap.

Not all pack sizes may be marketed

6.6 Special precautions for the disposal of unused veterinary medicinal

product or waste materials derived from the use of such products

THE PRODUCT IS EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do

not contaminate surface water or ditches with product or the used container. Any

unused veterinary medicinal product or waste material derived from such veterinary

medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

ECO Animal Health Ltd.

78 Coombe Road

New Malden

Surrey KT3 4QS

UNITED KINGDOM

8. MARKETING AUTHORISATION NUMBER

Vm 13277/4021

Generated by Unregistered Batch DOC TO PDF Converter 2011.3.827.1514, please register!

Revised: November 2011

AN. 01564/2010

Page 7 of 7

9. DATE OF FIRST AUTHORISATION

06 th

August 2007

10 DATE OF REVISION OF THE TEXT

November 2011

There are no safety alerts related to this product.

There are no news related to this product.

Other products with the same active ingredient